Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$42.21M+28.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aaron D. Berg
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 80
- Beta
- 0.76
- Country
- IE
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.00
Financials
Revenue
$42.21M+29.0%Net Income
$-7.65MEBITDA
$-11.33MFree Cash Flow
$40.26MEPS (diluted)
$-0.40Shares Outstanding (diluted)
20.82M+99.1%Operating Expenses
$26.96MCash & Debt
$314.65MReturn of Capital
$59.0KRevenue by Segment (annual)
$213.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $213.65M | $-38.80M | $-1.80 |
| 2024 | $228.61M | $-82.18M | $-4.00 |
| 2023 | $306.91M | $-59.11M | $-3.00 |
| 2022 | $369.19M | $-105.80M | $-5.20 |
| 2021 | $583.19M | $7.73M | $0.39 |
| 2020 | $614.06M | $-18.00M | $-0.94 |
| 2019 | $429.75M | $-22.64M | $-1.32 |
| 2018 | $229.21M | $-116.44M | $-7.80 |
| 2017 | $181.10M | $-67.86M | $-5.00 |
| 2016 | $130.08M | $-86.35M | $-8.20 |
| 2015 | $81.76M | $-115.20M | $-16.60 |
| 2014 | $54.20M | $-56.36M | $-6.40 |
| 2013 | $26.35M | $-166.23M | $-20.60 |
| 2012 | $0.00 | $-179.18M | $-24.80 |
Valuation
AMRNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (4)
- Newszacks.com·29d ago·Negative
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
View source ↗ - Newsglobenewswire.com·41d ago·Negative
…fit Following Icosapent Ethyl Treatment Cessation in Adherent Patients DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
View source ↗ - Newsglobenewswire.com·45d ago·Negative
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.10 per share
Typical surprise -87.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.02 vs $-0.01miss
- Wed, Apr 29$-0.09 vs $0.01miss
- Wed, Feb 25$0.01 vs $0.07miss
- Wed, Oct 29$0.01 vs $0.08miss
- Wed, Jul 30$-0.03 vs $-0.66beat
- Wed, May 7$-0.04 vs $-1.12beat
Estimates and results for AMRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMRN officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AMRN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.